Women across the United States are facing significant difficulties obtaining estrogen patches, a first-line treatment for menopause symptoms, due to ongoing supply shortages that have persisted since late 2023. The Food and Drug Administration’s drug shortage database currently lists multiple estrogen patch formulations as unavailable or in limited supply, affecting thousands of patients who rely on these hormone replacement therapies to manage hot flashes, night sweats, and other debilitating symptoms.
The shortage primarily impacts transdermal estradiol patches in various dosage strengths, manufactured by several pharmaceutical companies including major suppliers like Mylan and Novartis. Industry analysts attribute the disruption to a combination of manufacturing delays, increased demand following expanded awareness of menopause treatment options, and supply chain complications affecting the pharmaceutical adhesive components essential to patch production. Some manufacturers have cited quality control issues at production facilities, while others point to raw material sourcing challenges.
This shortage represents a critical access issue for menopausal women, as transdermal estrogen patches are often preferred over oral hormone therapy due to their lower risk of blood clots and more stable hormone delivery. For many patients, particularly those with contraindications to oral estrogen or those who have achieved symptom control with patches, the shortage forces difficult treatment changes. Healthcare providers report that patients are experiencing return of severe symptoms or facing delays in initiating therapy, significantly impacting quality of life and workplace productivity for women in their peak career years.
Clinicians are now exploring alternative approaches, including prescribing estrogen gels, oral formulations, or adjusting to available patch dosages through cutting patches—a practice not officially recommended by manufacturers. The American College of Obstetricians and Gynecologists has issued guidance encouraging physicians to work with patients on individualized solutions while the shortage persists. However, experts warn that this situation underscores the fragility of pharmaceutical supply chains and the need for better regulatory mechanisms to prevent disruptions in essential medications for women’s health.
